When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HEPA - Hepion Pharma +20% on launch of mid-stage CRV431 trial for NASH fibrosis
Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals (NASDAQ:HEPA) has completed the submission of a Phase 1 data memo and the Phase 2a protocol to the FDA, and intends to commence its Phase 2a clinical trial of CRV431 for the treatment of NASH fibrosis in June.
More news on: Hepion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,